Daniel N Cagney1, Nayan Lamba1,2, Sumi Sinha3, Paul J Catalano4,5, Wenya Linda Bi6, Brian M Alexander1, Ayal A Aizer1. 1. Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Department of Radiation Oncology, University of California, San Francisco, San Francisco. 4. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 5. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 6. Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
IMPORTANCE: Neurosurgical resection represents an important management strategy for patients with large, symptomatic brain metastases and increasingly is followed by stereotactic radiation as opposed to whole-brain radiation. Whether neurosurgical resection is associated with tumor spread beyond the resection site and adjuvant stereotactic radiation field remains unknown. OBJECTIVE: To characterize the association and incidence of pachymeningeal seeding with neurosurgical resection in patients with brain metastases treated with adjuvant stereotactic radiation. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of a consecutive sample of patients with newly diagnosed brain metastases managed with neurosurgical resection and stereotactic radiation (n = 318) vs radiation alone (n = 870) between 2001 and 2015. MAIN OUTCOMES AND MEASURES: Incidence of pachymeningeal seeding (dural and/or outer arachnoid) and leptomeningeal disease in patients treated with neurosurgical resection and stereotactic radiation vs radiation alone and the risk factors and outcomes associated with pachymeningeal seeding in patients treated with neurosurgical resection followed by stereotactic radiation. RESULTS: In 1188 patients with newly diagnosed brain metastases, 133 men and 185 women (mean [SD] age, 58.9 [11.5] years) underwent neurosurgical resection. Resection was found to be associated with pachymeningeal seeding (36 of 318 patients vs 0 of 870 patients; P < .001) but not leptomeningeal disease (hazard ratio [HR], 1.14; 95% CI, 0.73-1.77; P = .56). In total, 36 (8.4%) of 428 operations were complicated by pachymeningeal seeding, with a higher incidence noted with resection of previously irradiated vs unirradiated metastases (HR, 2.39; 95% CI, 1.25-4.57; P = .008). Patients with pachymeningeal seeding had relatively low rates of subsequent development of new brain metastases and leptomeningeal disease (8 [16%] of 51 and 6 [13%] of 48, respectively). Among patients with pachymeningeal seeding, neurologic death primarily owing to progressive pachymeningeal disease accounted for 26 (72%) of 36 deaths, but when treated with salvage radiation, 49.1% of patients survived 1 year or longer. CONCLUSIONS AND RELEVANCE: In the era of omission of adjuvant whole-brain radiation after neurosurgical resection, pachymeningeal seeding beyond the stereotactic radiation field represents a notable oncologic event that often proves difficult to salvage. However, in some patients, disease control can be achieved with radiotherapeutic approaches.
IMPORTANCE: Neurosurgical resection represents an important management strategy for patients with large, symptomatic brain metastases and increasingly is followed by stereotactic radiation as opposed to whole-brain radiation. Whether neurosurgical resection is associated with tumor spread beyond the resection site and adjuvant stereotactic radiation field remains unknown. OBJECTIVE: To characterize the association and incidence of pachymeningeal seeding with neurosurgical resection in patients with brain metastases treated with adjuvant stereotactic radiation. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of a consecutive sample of patients with newly diagnosed brain metastases managed with neurosurgical resection and stereotactic radiation (n = 318) vs radiation alone (n = 870) between 2001 and 2015. MAIN OUTCOMES AND MEASURES: Incidence of pachymeningeal seeding (dural and/or outer arachnoid) and leptomeningeal disease in patients treated with neurosurgical resection and stereotactic radiation vs radiation alone and the risk factors and outcomes associated with pachymeningeal seeding in patients treated with neurosurgical resection followed by stereotactic radiation. RESULTS: In 1188 patients with newly diagnosed brain metastases, 133 men and 185 women (mean [SD] age, 58.9 [11.5] years) underwent neurosurgical resection. Resection was found to be associated with pachymeningeal seeding (36 of 318 patients vs 0 of 870 patients; P < .001) but not leptomeningeal disease (hazard ratio [HR], 1.14; 95% CI, 0.73-1.77; P = .56). In total, 36 (8.4%) of 428 operations were complicated by pachymeningeal seeding, with a higher incidence noted with resection of previously irradiated vs unirradiated metastases (HR, 2.39; 95% CI, 1.25-4.57; P = .008). Patients with pachymeningeal seeding had relatively low rates of subsequent development of new brain metastases and leptomeningeal disease (8 [16%] of 51 and 6 [13%] of 48, respectively). Among patients with pachymeningeal seeding, neurologic death primarily owing to progressive pachymeningeal disease accounted for 26 (72%) of 36 deaths, but when treated with salvage radiation, 49.1% of patients survived 1 year or longer. CONCLUSIONS AND RELEVANCE: In the era of omission of adjuvant whole-brain radiation after neurosurgical resection, pachymeningeal seeding beyond the stereotactic radiation field represents a notable oncologic event that often proves difficult to salvage. However, in some patients, disease control can be achieved with radiotherapeutic approaches.
Authors: A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245
Authors: R A Patchell; P A Tibbs; J W Walsh; R J Dempsey; Y Maruyama; R J Kryscio; W R Markesbery; J S Macdonald; B Young Journal: N Engl J Med Date: 1990-02-22 Impact factor: 91.245
Authors: Amparo Wolf; Bernadine Donahue; Joshua S Silverman; Abraham Chachoua; Jean K Lee; Douglas Kondziolka Journal: J Neurooncol Date: 2017-05-23 Impact factor: 4.130
Authors: Matthew D Johnson; Vladimir Avkshtol; Andrew M Baschnagel; Kurt Meyer; Hong Ye; Inga S Grills; Peter Y Chen; Ann Maitz; Rick E Olson; Daniel R Pieper; Daniel J Krauss Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-19 Impact factor: 7.038
Authors: Edina C Wang; Andrew J Huang; Karen E Huang; Emory R McTyre; Hui-Wen Lo; Kounosuke Watabe; Linda Metheny-Barlow; Adrian W Laxton; Stephen B Tatter; Roy E Strowd; Michael D Chan; Brandi R Page Journal: J Clin Neurosci Date: 2017-05-13 Impact factor: 1.961
Authors: Riccardo Soffietti; Martin Kocher; Ufuk M Abacioglu; Salvador Villa; François Fauchon; Brigitta G Baumert; Laura Fariselli; Tzahala Tzuk-Shina; Rolf-Dieter Kortmann; Christian Carrie; Mohamed Ben Hassel; Mauri Kouri; Egils Valeinis; Dirk van den Berge; Rolf-Peter Mueller; Gloria Tridello; Laurence Collette; Andrew Bottomley Journal: J Clin Oncol Date: 2012-12-03 Impact factor: 44.544
Authors: R A Patchell; P A Tibbs; W F Regine; R J Dempsey; M Mohiuddin; R J Kryscio; W R Markesbery; K A Foon; B Young Journal: JAMA Date: 1998-11-04 Impact factor: 56.272
Authors: Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer Journal: Neuro Oncol Date: 2017-10-19 Impact factor: 12.300
Authors: Timothy K Nguyen; Arjun Sahgal; Jay Detsky; Eshetu G Atenafu; Sten Myrehaug; Chia-Lin Tseng; Zain Husain; Chris Heyn; Pejman Maralani; Mark Ruschin; James Perry; Hany Soliman Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Desmond A Brown; Victor M Lu; Benjamin T Himes; Terry C Burns; Alfredo Quiñones-Hinojosa; Kaisorn L Chaichana; Ian F Parney Journal: Clin Exp Metastasis Date: 2020-01-16 Impact factor: 5.150
Authors: Emilie Le Rhun; Patrick Devos; Johannes Weller; Katharina Seystahl; Francesca Mo; Anette Compter; Anna S Berghoff; Joost L M Jongen; Fabian Wolpert; Roberta Rudà; Dieta Brandsma; Martin van den Bent; Matthias Preusser; Ulrich Herrlinger; Michael Weller Journal: Neuro Oncol Date: 2021-07-01 Impact factor: 12.300
Authors: Evan D Bander; Melissa Yuan; Anne S Reiner; Katherine S Panageas; Åse M Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss Journal: Neurooncol Pract Date: 2021-01-21